Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDialysis/Renal ReplacementAetna Crit-Line In-Line Monitor Coverage Update | …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0373

    Crit-Line In-Line Monitor

    Customize your policy alerts

    Sign up for Aetna Policy 0373 alerts

    Get alerted when Policy 0373 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy describes Aetna's coverage stance for the Crit-Line in-line monitor used to measure hematocrit and oxygen saturation during hemodialysis and which members/providers it affects.

    Policy Summary
    PayerAetna
    PolicyCrit-Line In-Line Monitor
    Policy CodePolicy 0373
    Change TypeNo material change
    Effective DateMar 8, 2000
    Last ReviewJun 6, 2023
    Next Review DateApr 11, 2024
    Key ActionDo not submit claims for the Crit-Line In-Line Monitor for monitoring hematocrit or oxygen saturation because the device is considered experimental and investigational for these indications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    investigationalcoverage stance for device
    510(k) 1995FDA clearance
    4–56study sizes cited

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    0373policy id
    ~20links provided

    Coverage Determination

    Not established as medically necessary / investigational

    Aetna's coverage conclusion for the Crit-Line In-Line Monitor

    Main stance: The Crit-Line In-Line Monitor is considered experimental and investigational for monitoring hematocrit and oxygen saturation because its effectiveness in avoiding intra-dialytic morbid events, preventing ischemia due to intra-dialytic hypoxia, and determining access re-circulations has not been proven.

    Statement of noncoverage stance based on insufficient evidence.

    Use of the Crit-Line In‑Line Monitor for monitoring hematocrit and oxygen saturation is considered experimental and investigational and is excluded from coverage under this policy.

    The device is considered investigational because the effectiveness of the Crit‑Line In‑Line Monitor in avoiding intra‑dialytic morbid events, in preventing ischemia due to intra‑dialytic hypoxia, and in determining access re‑circulations has not been demonstrated. Clinical reports (for example Steuer et al.) have evaluated blood‑volume monitoring and tolerance of additional fluid removal but do not establish that use of the Crit‑Line reduces intradialytic morbidity or prevents ischemic events.

    Coding and Billing

    Other CPT/HCPCS codes related to this CPBmixed
    90935Hemodialysis procedure with single evaluation by a physician or other qualified health care professional.
    90937Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription.
    S9335Home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately), per diem.
    ICD-10 codes not covered for indications listed in the CPB (examples)ICD-10Not Covered
    N17.0 - N17.9Acute kidney failure.
    N18.1 - N18.9Chronic kidney disease (CKD).
    N19Unspecified kidney failure.
    N26.1Unspecified contracted kidney.
    N26.9Unspecified contracted kidney.
    Z49.31Encounter for adequacy testing for hemodialysis.
    Z49.32Encounter for adequacy testing for peritoneal dialysis.
    Z99.2Dependence on renal dialysis.

    Provider Notice, Authorization & Billing Guidance

    Denial Risk

    Denial Risk for Use

    The Crit-Line In-Line Monitor is considered experimental and investigational for monitoring hematocrit and oxygen saturation because its effectiveness for avoiding intra-dialytic morbid events, preventing ischemia due to intra-dialytic hypoxia, and determining access re-circulations has not been proven. Use of this device may be denied as not medically necessary.

    • Experimental / investigational for monitoring hematocrit and oxygen saturation
    • May be denied for the uses described due to insufficient evidence
    Prior Authorization

    Prior Authorization Not Specified

    Aetna does not specify any prior authorization codes or prior authorization procedure for the Crit-Line In-Line Monitor in this policy. Providers should follow standard plan-specific prior authorization processes when applicable and verify requirements with the member's benefit plan.

    Device Background

    The Crit‑Line In‑Line Monitor is an optical, in‑line monitoring system that measures hematocrit and oxygen saturation in real time by placing a sterile disposable blood chamber and sensor in‑line between the arterial tubing and the dialyzer. Readouts include hematocrit, percent blood‑volume change, and oxygen saturation displayed graphically during hemodialysis.

    Definitions and Key Terms

    Crit-Line In-Line Monitor — key properties of the device
    Device typeOptical in-line monitor that measures hematocrit and oxygen saturation in real time
    Measurement methodOptical sensor attached to a sterile disposable blood chamber placed in-line between the arterial tubing and the dialyzer
    Displayed/recorded outputsHematocrit, percent blood volume change (derived from hematocrit), and oxygen saturation
    Blood chamberSterile disposable blood chamber placed in the dialysis tubing circuit
    Analytic basis for hematocritDetermines hematocrit from hemoglobin absorption and red blood cell scattering properties
    Intra-dialytic morbid events — examples
    Policy Summary
    PayerAetna
    PolicyCrit-Line In-Line Monitor
    Policy CodePolicy 0373
    Change TypeNo material change
    Effective DateMar 8, 2000
    Last ReviewJun 6, 2023
    Next Review DateApr 11, 2024
    Key ActionDo not submit claims for the Crit-Line In-Line Monitor for monitoring hematocrit or oxygen saturation because the device is considered experimental and investigational for these indications.
    SourceLink
    On This Page
    Coverage DeterminationCoding and BillingProvider Notice, Authorization & Billing GuidanceDevice BackgroundDefinitions and Key Terms
  1. No specific prior authorization codes listed in this policy
  2. Verify member-specific prior authorization requirements with the plan
  3. Documentation Required

    Provider Documentation / Authorization Absence

    No provider documentation or authorization instructions are provided in this policy. Providers must retain appropriate medical records to support services rendered and consult the member's plan for any documentation or authorization requirements.

    • No policy-level documentation or authorization steps described
    • Maintain clinical records to justify medical necessity if services are rendered
    Step Therapy

    Step Therapy Not Specified

    There are no step therapy requirements described for the Crit-Line In-Line Monitor in this policy.

    • No step therapy or prior treatment sequence required per this policy
    Billing Rule

    Coding and Documentation References

    Relevant coding references listed in the source include related hemodialysis and home therapy codes. ICD-10 diagnosis codes are listed as not covered for indications in the CPB (examples include acute and chronic kidney failure codes). Providers should bill using the applicable hemodialysis procedure or HCPCS codes when appropriate and note that no specific CPT/HCPCS code is designated for the Crit-Line device itself.

    • Related CPT: 90935, 90937
    • Related HCPCS: S9335
    • ICD-10 codes listed as not covered for CPB indications include N17.x, N18.x, N19, N26.x, Z49.31, Z49.32, Z99.2
    • No specific CPT/HCPCS code assigned to the Crit-Line In-Line Monitor in this policy
    Note

    Provider Guidance / Additional Information

    This policy does not provide provider-facing actions beyond the above notices. For additional information, refer to Aetna clinical policy resources and the member's benefit plan documents.

    • See Aetna Clinical Policy Bulletins and plan-specific documents for more information
    DefinitionAdverse events occurring during dialysis (examples listed below)
    Examples — hemodynamicHypotension during hemodialysis due to excessive plasma volume depletion
    Examples — sensory/muscularMuscle cramps and lightheadedness occurring during dialysis sessions
    Examples — gastrointestinalNausea occurring intra-dialytically
    Clinical relevanceContinuous monitoring has been studied to detect hypoxia episodes (oxygen saturation < 90%) that may relate to intra-dialytic morbidity and silent ischemia